Longaeva Partners’s Medline Inc MDLN Stock Holding History

Longaeva Partners’s Portfolio MDLN Stock Details MDLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-635,000	Closed	-$28.3M	–	433
2026 Q1	$28.3M	Buy	635,000 +544,762	+604%	+$24.1M	1.05%	24
2025 Q4	$3.79M	Buy	+90,238	New	+$3.81M	0.32%	74

Other funds holding MDLN

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

HFCIX

H&F Corporate Investors X San Francisco, California $2.8B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Longaeva Partners's MDLN Position: Q2 2026 in Review

Longaeva Partners sold out of Medline Inc (MDLN) in Q2 2026, closing a stake of 635,000 shares — an estimated $28.3M sold.

Longaeva Partners first reported a position in MDLN in Q4 2025 and held it in 2 quarters. The position peaked at $28.3M in Q1 2026. 409 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

Longaeva Partners reported no remaining Medline Inc position as of Q2 2026 after selling out during the quarter.
Longaeva Partners sold 635,000 Medline Inc shares in Q2 2026, an estimated $28.3M.
Longaeva Partners first reported a position in Medline Inc in Q4 2025 and held it in 2 quarters.
Longaeva Partners's Medline Inc position peaked at $28.3M in Q1 2026.
409 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.